Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 9, 2015, Pages 385.e15-385.e20

  Kato, Taku ^a   Mizutani, Kosuke ^a   Kameyama, Koji ^a   Kawakami, Kyojiro ^b   Fujita, Yasunori ^b   Nakane, Keita ^c   Kanimoto, Yusuke ^c   Ehara, Hidetoshi ^d   Ito, Hiroyasu ^a   Seishima, Mitsuru ^a   Deguchi, Takashi ^a   Ito, Masafumi ^b  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c Chutoen General Medical Center   (Japan)

^d ASAHI UNIVERSITY   (Japan)

Author keywords

Cabazitaxel; Castration resistant prostate cancer; Docetaxel; Exosomes; Multidrug resistance protein 1 MDR1; P glycoprotein P gp

Indexed keywords

CABAZITAXEL; DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL KILLING; CELL LYSATE; CELL VIABILITY; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG SENSITIVITY; EXOSOME; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VERY ELDERLY; WESTERN BLOTTING; WST ASSAY; BLOOD; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXOSOMES; HUMANS; MALE; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA, SMALL INTERFERING; TAXOIDS; TRANSFECTION;

EID: 84940467327     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.04.019     Document Type: Article

References (35)

1. Hsing A.W., Chokkalingam A.P. Prostate cancer epidemiology. Front Biosci 2006, 11:1388-1413.
2. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999, 281:1591-1597.
3. Loblaw D.A., Mendelson D.S., Talcott J.A., Virgo K.S., Somerfield M.R., Ben-Josef E., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004, 22:2927-2941.
4. Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011, 65:1180-1192.
5. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
6. Marchetti S., Mazzanti R., Beijnen J.H., Schellens J.H. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007, 12:927-941.
7. Xu H., Hong F.Z., Li S., Zhang P., Zhu L. Short hairpin RNA-mediated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/Taxol. Chin J Cancer Res 2012, 24:138-142.
8. Xia Z., Zhang L., Chen Q., Royal C., Yu Z., Liu Z., et al. Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol Med Rep 2009, 2:579-584.
9. Takeda M., Mizokami A., Mamiya K., Li Y.Q., Zhang J., Keller E.T., et al. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007, 67:955-967.
10. Abdulla A., Kapoor A. Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011, 5:120-133.
11. van Zuylen L., Verweij J., Nooter K., Brouwer E., Stoter G., Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000, 6:2598-2603.
12. Ganju A., Yallapu M.M., Khan S., Behrman S.W., Chauhan S.C., Jaggi M. Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Update 2014, 17:13-23.
13. Paller C.J., Antonarakis E.S. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011, 5:117-124.
14. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
15. Caffo O., Pappagallo G., Brugnara S., Caldara A., di Pasquale M.C., Ferro A., et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 2012, 79:644-649.
16. Heck M.M., Thalgott M., Retz M., Wolf P., Maurer T., Nawroth R., et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int 2012, 110:E635-E640.
17. Loriot Y., Massard C., Gross-Goupil M., Di Palma M., Escudier B., Bossi A., et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010, 46:1770-1772.
18. Johnstone R.M., Bianchini A., Teng K. Reticulocyte maturation and exosome release: transferrin receptor containing exosomes shows multiple plasma membrane functions. Blood 1989, 74:1844-1851.
19. Harding C., Heuser J., Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983, 97:329-339.
20. Pan B.T., Teng K., Wu C., Adam M., Johnstone R.M. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 1985, 101:942-948.
21. Duijvesz D., Luider T., Bangma C.H., Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 2011, 59:823-831.
22. Hessvik N.P., Sandvig K., Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet 2013, 4:36.
23. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009, 10:42-46.
24. Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010, 70:1501-1512.
25. Mizutani K., Terazawa R., Kameyama K., Kato T., Horie K., Tsuchiya T., et al. Isolation of prostate cancer-related exosomes. Anticancer Res 2014, 34:3419-3423.
26. Fujita Y., Kojima K., Ohhashi R., Hamada N., Nozawa Y., Kitamoto A., et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010, 285:19076-19084.
27. Kato T., Fujita Y., Nakane K., Kojima T., Nozawa Y., Deguchi T., et al. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression. Biochem Biophys Res Commun 2012, 417:966-971.
28. Bhangal G., Halford S., Wang J., Roylance R., Shah R., Waxman J. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 2000, 5:118-121.
29. Corcoran C., Rani S., O'Brien K., O'Neill A., Prencipe M., Sheikh R., et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PloS One 2012, 7:e50999.
30. Vrignaud P., Semiond D., Lejeune P., Bouchard H., Calvet L., Combeau C., et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013, 19:2973-2983.
31. Kharaziha P., Chioureas D., Rutishauser D., Baltatzis G., Lennartsson L., Fonseca P., et al. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget 2015, in press.
32. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987, 84:265-269.
33. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987, 84:7735-7738.
34. Arceci R.J., Croop J.M., Horwitz S.B., Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci U S A 1988, 85:4350-4354.
35. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989, 86:695-698.